Most people know hydralazine as one of those dependable, decades-old medications tucked into hypertension treatment plans.
What has rarely been questioned, however, is how the drug actually works.
Now, a research team from the University of Pennsylvania has uncovered a clue that may extend far beyond blood pressure — and into the realm of aggressive brain cancer.
Their investigation began with a basic scientific puzzle: despite more than 70 years of clinical use, hydralazine’s precise molecular target had never been clearly identified.
Also read: Why your skin dries out - and what you can do about it
The researchers designed a tagged version of the drug, allowing them to trace where it attached inside living cells. One enzyme, known as ADO, repeatedly appeared as the primary interaction point.
ADO plays a role in regulating vascular tension, which fits with hydralazine’s blood-pressure-lowering abilities.
But the enzyme has also surfaced in previous studies of glioblastoma, a fast-growing brain tumour with limited treatment options and survival rates that have barely improved in decades.
That overlap encouraged the team to shift their attention from hypertension to cancer biology.
Also read: Weather has little impact on how many calories you burn
In laboratory experiments, glioblastoma cells exposed to hydralazine did not die outright.
Instead, they entered a slowed, dormant-like state — a process researchers refer to as senescence.
While not a cure, pushing cells into this stalled mode can significantly limit tumor expansion, offering a different therapeutic angle than traditional cell-killing treatments.
Scientists unrelated to the study told Medical News Today that the findings introduce a fresh way of thinking about managing highly resistant cancers.
Also read: This new vaccine aims to prevent lung cancer at its earliest stage
Hydralazine’s long safety record and low cost add to the interest, though experts caution that the work remains entirely preclinical.
Tumour biology is notoriously adaptable, and long-term success would likely require carefully timed or combination approaches.
Even so, the discovery opens the possibility that drugs designed for familiar conditions could hold unexpected value in some of medicine’s most challenging diseases — provided future studies confirm the potential first seen in the lab.
Sources: Medical News Today and Science Advances
Also read: Cardiologist reveals 15 simple ways to lower blood pressure